Who Owns Stoke Therapeutics Inc (STOK)? 13F Institutional Holders (Q2 2026)

STOK ranks #3026 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

STOK is a top-conviction position for Lynx1 Capital Management LP — at 15.3% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in STOK belongs to BlackRock, Inc., but the position matters far more to Lynx1 Capital Management LP, who has 15.3% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Farther Finance Advisors, LLC has trimmed its STOK position for two straight quarters, cutting it by $838.0 while still holding $442.0.

STOK is up 2.8% today, and institutions have been net buyers of $240.4M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

STOK reported a net loss of $207.9M over the trailing twelve months.

• Not yet profitable — net loss of $207.9M over the trailing twelve months
• Revenue declined 86.2% year over year
• Net income declined year over year, from $52.5M to -$207.9M
• Generated $45.6M in positive operating cash flow
• Current ratio of 5.28x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.19x equity — within a conventional range